4/30/2008 | PP | New Issue: Nastech sets terms on $7.93 million direct offering of shares, warrants
|
4/25/2008 | PP | New Issue: Nastech plans $7.93 million direct offering of shares, warrants
|
1/22/2008 | CV | Nastech Pharmaceutical files $50 million shelf registration
|
11/1/2006 | BT | Nastech quarterly revenue up more than $4 million
|
10/19/2006 | BT | Nastech files $125 million stock shelf
|
9/26/2006 | BT | Nastech gets $1.9 million NIH grant for RNAi flu therapeutics
|
9/19/2006 | BT | Nastech begins phase 1 study of insulin nasal spray for diabetes
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/29/2006 | BT | Nastech gets grant to develop small-interfering RNA therapeutics to treat influenza
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/14/2006 | BT | Nastech starts dosing in study of PYY(3-36) for obesity
|
7/25/2006 | BT | Nastech gets patent for Peptide YY obesity treatment
|
7/25/2006 | BT | Market Commentary: Encysive plunges 40%; Momenta gains 38%; Nastech rises; Enzon up; Connetics firms
|
7/13/2006 | BT | Nastech's calcitonin-salmon nasal spray denied by FDA
|
7/13/2006 | BT | Market Commentary: Nastech loses 15% on FDA snub; Novavax retreats; Anadys moves up; Acadia slumps; Illumina lifted
|
6/27/2006 | BT | Nastech reports positive findings on nasal treatment for diabetes, delivery of large molecules
|
6/26/2006 | BT | Nastech demonstrates parathyroid hormone nasal spray delivers drug in elderly patients
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
6/26/2006 | BT | Nastech, Amylin to develop nasal spray formulation of exenatide for diabetes
|
6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
6/7/2006 | BT | Nastech files application for anti-obesity nasal spray
|
6/6/2006 | BT | Nastech, Procter & Gamble form supply agreement for osteoporosis spray
|
4/28/2006 | BT | Nastech's parathyroid hormone nasal spray well tolerated in phase 1 study
|
3/21/2006 | BT | Market Commentary: Novavax, Nastech buck uptrend in flu names; NitroMed exec exits applauded; BioMarin off on deals
|
3/16/2006 | BT | Nastech says RNAi therapeutics program for influenza successful
|
3/16/2006 | BT | Market Commentary: Novavax, Nastech flu names on a tear; BioMarin higher on trial; Elite bobs, Titan slips on PIPEs
|
3/15/2006 | BT | Nastech signs multi-compound feasibility agreement with Novo Nordisk
|
3/2/2006 | BT | Merck terminates deal with Nastech to develop PYY3-36 nasal spray for obesity
|
3/2/2006 | BT | Market Commentary: Genentech recoups from Avastin blow; ImClone slumps; Nastech drops; NitroMed strikes new low
|
2/28/2006 | BT | Nastech's facility approved for commercial manufacturing of osteoporosis nasal spray
|
2/23/2006 | BT | Nastech acquires RNAi therapeutics program targeting influenza
|
2/23/2006 | BT | Market Commentary: Kos crashes on results, warning; GTC garroted by E.U. rejection; Nastech higher; Biovail mixed
|
2/1/2006 | BT | Nastech, Procter & Gamble to collaborate on PTH1-34 nasal spray for treatment of osteoporosis
|
12/14/2005 | BT | Nastech says new data demonstrates four new lipids that may enhance drug delivery
|
11/17/2005 | BT | Nastech's rheumatoid arthritis treatment uses different mechanism than existing drugs, study finds
|
8/25/2005 | BT | New Issue: Nastech raises $23.3 million in follow-on at $13.50, discounted from $13.61 close
|
8/25/2005 | BT | Market Commentary: Nastech rises in face of follow-on deal; Amylin up on takeover buzz; Antigenics convertible finds buyers
|
8/8/2005 | BT | Market Commentary: Isis declines on earnings, Lilly note conversion but 5.5% convert finds bids; Quest, LabOne higher
|
8/5/2005 | BT | Nastech withdraws plan to sell 1.5 million share in follow-on offering
|
8/5/2005 | BT | Market Commentary: Advanced Life Sciences IPO gets off at big price cut; AtriCure IPO bounces; Coley's IPO ahead
|
8/4/2005 | BT | Market Commentary: ZymoGenetics follow-on upsized but discounted; Eli Lilly sells $1.5 billion variable floaters
|
8/2/2005 | BT | Market Commentary: Anadys up on Novartis details; Ariad, Nastech, ZymoGenetics mixed; Myogen zooms; Isis gains
|
8/1/2005 | BT | Nastech plans 1.5 million share follow-on; reports slightly wider second-quarter loss
|
8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|